论文部分内容阅读
对2017年新公开的专利进行分析发现,抗体工程领域的专利主要通过基因工程、蛋白质工程、细胞融合等技术制备新抗体,用于治疗肿瘤、免疫性疾病、感染性疾病等疾病。主要专利权人不仅包括罗氏、基因泰克、诺华等全球知名的医药巨头,还包括加州大学、德克萨斯大学、哈佛大学等高校与研究院所。其中,
The analysis of newly published patents in 2017 found that the patents in the field of antibody engineering mainly prepare new antibodies through technologies such as genetic engineering, protein engineering, cell fusion and the like for the treatment of diseases such as tumors, immune diseases and infectious diseases. The major patentees include not only the world-renowned pharmaceutical giants such as Roche, Genentech, Novartis, but also universities and research institutes such as the University of California, the University of Texas, and Harvard University. among them,